Phase I safety and pharmacokinetics study of micronized atovaquone in human immunodeficiency virus-infected infants and children

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 6, 1998, Pages 1315-1318

  Hughes, Walter ^a   Dorenbaum, Alejandro ^b   Yogev, Ram ^c   Beauchamp, Belinda ^d   Xu, Jing ^e   McNamara, James ^f   Moye, John ^g   Purdue, Lynette ^f   Van Dyke, Russell ^h   Rogers, Michael ⁱ   Sadler, Brian ⁱ  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031835165     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.6.1315     Document Type: Article

References (19)

1. Araujo, F. G., J. Huskinson, and J. S. Remington. 1991. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob. Agents Chemother. 35:293-299.
2. Araujo, F. G., T. Lin, and J. S. Remington. 1993. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. J. Infect. Dis. 167:494-497.
3. Centers for Disease Control and Prevention. 1995. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. Morbid. Mortal. Weekly Rep. 44:1-34.
4. Cotton, D. 1995. Atovaquone (Mepron) suspension approved by FDA. AIDS Clin. Care 7:62.
5. Davies, C. S., M. Pudney, P. J. Matthew, and R. E. Sinden. 1989. The casual prophylactic activity of the novel hydroxyquinone 566C80 against Plasmodium berghei infection in rats. Acta Leiden 58:115-128.
6. Dixon, R., A. L. Pozniak, H. M. Watt, P. Rolan, and J. Posne. 1996. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob. Agents Chemother. 40:556-560.
7. Dohn, M. H., W. G. Winberg, R. A. Torres, S. E. Follansbee, P. T. Caldwell, J. D. Scott, J. C. Gathe, D. P. Haghighat, J. H. Sampson, J. Spotkov, S. C. Deresinski, R. D. Meyer, and D. J. Lancaster. 1994. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann. Intern. Med. 121:174-180.
8. 7a. Glaxo-Wellcome, Inc. Data on file.
9. Hughes, W. T., G. Leoung, F. Kramer, S. Bozzette, S. Safrin, P. Frame, N. Clumack, H. Masur, D. Lancaster, and C. Chan. 1993. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N. Engl. J. Med. 328:1521-1527.
10. Hughes, W. T., and H. S. Oz. 1995. Successful prevention and treatment of babesiosis with atovaquone. J. Infect. Dis. 172:1042-1046.
11. Hughes, W. T., S. W. LaFon, J. D. Scott, and H. Masur. 1995. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J. Infect. Dis. 171:1295-1301.
12. Hughes, W. T., V. L. Gray, W. E. Gutteridge, V. S. Latter, and M. Pudney. 1990. Efficacy of hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrob. Agents Chemother. 34:225-228.
13. Ittarat, I., W. Asawamahasakda, M. S. Bartlett, J. W. Smith, and S. R. Meshnick. 1995. Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob. Agents Chemother. 39: 325-328.
14. Kovacs, J. A. 1992. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. Lancet 340:637-638.
15. Looareesuwan, S., C. Viravan, H. K. Webster, D. E. Kyle, and D. B. Hutchinson. 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute, uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. 54:62-66.
16. Pagano, G., W. Kennedy, S. Weller, R. McKinney, N. Brown, and W. Hughes. 1993. The safety and pharmacokinetics of atovaquone in immunosuppressed children. In Abstracts of the IX International Conference on AIDS.
17. Radloff, P. D., J. Phillips, and M. Nkeyi. 1996. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 347:1511-1514.
18. Sadler, B. M., and M. R. Blum. 1993. Relationship between steady-state plasma concentrations of atovaquone and the use of various concomitant medications in AIDS patients with Pneumocystis carinii pneumonia, abstr. P.O.-B31-2212, p. 504. In Abstracts of the IX International Conference on AIDS.
19. Studenberg, S. D., J. D. Long, J. H. Woolf, C. J. Bruner, D. Wilson, and J. L. Woolley. 1995. A robotics-based liquid chromatographic assay for the measurement of atovaquone in plasma. J. Pharm. Biomed. Anal. 13:1383-1393.